Active Phospholipase A2 Group VII (PLA2G7)

LpPLA2; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated

ACTIVITY TEST

Figure. The binding activity of LpPLA2 with PTPRN.
Phospholipase A2, Lipoprotein Associated (LpPLA2) also known as platelet-activating factor acetylhydrolase (PAF-AH) is a phospholipase A2 enzyme. LpPLA2 is platelet-activating factor (PAF) acetylhydrolase, a secreted enzyme that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate. Besides, Protein Tyrosine Phosphatase Receptor Type N (PTPRN) has been identified as an interactor of LpPLA2, thus a binding ELISA assay was conducted to detect the interaction of recombinant human LpPLA2 and recombinant human PTPRN. Briefly, LpPLA2 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100uL were then transferred to PTPRN-coated microtiter wells and incubated for 2h at 37℃. Wells were washed with PBST and incubated for 1h with anti-LpPLA2 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of LpPLA2 and PTPRN was shown in Figure 1, and this effect was in a dose dependent manner.

USAGE

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Science & Sports The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women ScienceDirect: S0765159710000262
Metabolic Syndrome and Related Disorders Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease Wiley: source
34 Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study PubMed: 22240497
PLoS ONE Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo PubMed: PMC3759413
China Pharmacy Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats Source
Atherosclerosis Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Pubmed: 23958269
Journal of Diabetes Research Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus Hindawi: 278063
Health The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia Scirp:Source
Biology Bulletin In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood Springer:Source
Gynecol Endocrinol. Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. Pubmed:24397392
Journal of Diabetes Research Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus Pubmed:24818163
Metabolism. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes Pubmed:25034387
J Am Heart Assoc Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients PubMed: 26374297
Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie V Ebscohost
Endocrinol Metab (Seoul). Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome pmc:PMC4803547
Clin Pharmacol Ther.  Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery Pubmed:25773594
Lipids in Health and Disease Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … articles:10.1186
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
APA867Hu01 Active Phospholipase A2 Group VII (PLA2G7) Cell culture; Activity Assays.
RPA867Hu01 Recombinant Phospholipase A2 Group VII (PLA2G7) Positive Control; Immunogen; SDS-PAGE; WB.
PAA867Hu01 Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7) WB; IHC; ICC; IP.
LAA867Hu81 FITC-Linked Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7) WB; IHC; ICC; IF.
LAA867Hu71 Biotin-Linked Polyclonal Antibody to Phospholipase A2 Group VII (PLA2G7) WB; IHC; ICC.
MAA867Hu22 Monoclonal Antibody to Phospholipase A2 Group VII (PLA2G7) WB; IHC; ICC; IP.
SEA867Hu ELISA Kit for Phospholipase A2 Group VII (PLA2G7) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA867Hu CLIA Kit for Phospholipase A2 Group VII (PLA2G7) Chemiluminescent immunoassay for Antigen Detection.